HCC unmet medical need
What is hepatocellular carcinoma (HCC)?
A cancer arising from the liver cells (hepatocytes). Liver damage, manifested by cirrhosis (scarring), is a primary risk factor for liver cancer. Cirrhosis may be caused by viral hepatitis, primarily hepatitis B and C, alcohol abuse, hemochromatosis, certain autoimmune diseases of the liver, and other diseases that result in chronic inflammation of the liver.
Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136:E359-86; Ferlay J et al. Global Cancer Statistics. Ca Cancer J Clin 2011, 61:69–90; Siegel R et al. Cancer Statistics, 2017. Ca Cancer J Clin 2017, 67:7–30; Siegel R et al. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012, 21:411-416; McGlynn K et al. The Global Epidemiology of Hepatocellular Carcinoma, Present and Future Clin Liver Dis. 2011,15,223-x
The sixth most common cancer worldwide
749,000 new cases/year
In 2017, US estimated new cases for liver cancer is 40.710
Third cause of cancer related death worldwide
692,000 cases/year
Accounts for 7% of all cancers worldwide
40% of them have poor liver function – not eligible for standard treatment
50% are diagnosed with advanced disease – incurable disease
Systemic treatment in patients with advanced disease cause quality of life deterioration
HCC treatment limitations
Treatment costs limit the access to new agents.
90% of patients are diagnosed with advanced disease and less then 50% have a treatment option.
Best systemic treatment will extent median survival by less then 4 month.
It is associated with poor liver function (cirrhosis) in 85% of the cases.
40% of patients are not fit enough for standard treatment.
Future targeted treatment programs
PROSTATA
CANCER
1.095.000
cases diagnosed
99%
five years survival
BREAST
CANCER
1.671.000
cases diagnosed
90%
five years survival
PANCREATIC
CANCER
223.000
cases diagnosed
8%
five years survival
GIOBLASTOMA
MULTIFORME
240.000
cases diagnosed
5%
five years survival
NON-SMALL CELL
LUNG CANCER
1.242.000
cases diagnosed
24%
five years survival
OVARIAN
CANCER
230.000
cases diagnosed
47%
five years survival
GASTRIC
CANCER
27.510
cases diagnosed
31%
five years survival
from Globocan 2012 and Globocan Incidence 2012
